United Therapeutics (UTHR) announced that the FDA has cleared its investigational new drug application to initiate a clinical study of the company’s investigational UKidney derived from a 10 gene-edited source pig. The study will enroll an initial cohort of six end-stage renal disease patients, expanding to up to 50 participants, and is intended to support a biologics license application with the FDA. United Therapeutics expects the first xenotransplant in this trial to be performed around mid-year 2025.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UTHR:
- United Therapeutics to Present at J.P. Morgan Conference
- Trump Trade: New administration to invest $20B to build data centers
- United Therapeutics price target raised to $475 from $415 at UBS
- Biotech Alert: Searches spiking for these stocks today
- United Therapeutics President Michael Benkowitz sells $3.7M in shares